Situated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Credit: Amgen Inc. Amgen has inaugurated its new drug substance facility ... combination therapy for treating adults with KRAS G12C-mutated metastatic colorectal cancer. Give your business an edge ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

with the KRAS G12C mutation, and according to Amgen patients in England, Wales and Scotland will be the first in Europe to receive the drug. The NHS will begin to offer the drug to eligible lung ...

Genfleet Therapeutics and InxMed all presented new clinical data on KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), going after the same mutation and indication as Amgen’s Lumakras ...

Preliminary data from the phase 2 study (NCT05608044), presented at the 2025 Gastrointestinal Cancers Symposium, showed that combining balstilimab with botensilimab improved the objective response ...

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...